Actively Recruiting

Phase Not Applicable
FEMALE
ID07603895

Evaluation of the Efficacy of a Probiotic Product as an Adjuvant Treatment for Vulvovaginal Candidiasis

Led by Bioithas SL · Updated on 2026-05-22

60

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

The trial investigates the use of the probiotic supplement Bioithas WOMAN4 as an additional treatment alongside antifungal medication for women with clinically suspected vulvovaginal candidiasis (VVC). This open-label, randomized clinical trial includes a control group and focuses on evaluating symptom improvement and microbiological changes over a 4-week treatment period. The study aims to compare outcomes between women receiving only antifungal treatment and those also taking the probiotic supplement. Participants will be randomly assigned to either the treatment group, which receives the probiotic supplement in addition to prescribed antifungal therapy, or the control group, which receives antifungal treatment alone. The probiotic is provided as a bottle containing 30 capsules, taken during the 4-week intervention. The study includes two on-site visits: a baseline visit where clinical data and vaginal samples are collected, and a final visit at week 4, where the same assessments are repeated, including symptom scoring and microbiological cultures. During the study visits, researchers will collect demographic and gynecological history, record symptoms such as vaginal discharge, itching, burning, irritation, and pain during intercourse, and measure vaginal pH. Vaginal samples will be cultured to detect Candida and assess Lactobacillus levels. Treatment adherence in the probiotic group will be monitored by capsule counts. The main outcome measured is the difference in symptom absence after 4 weeks between groups, along with secondary outcomes like symptom scores, microbiological culture results, and adherence. Any adverse events and additional treatments during follow-up will also be recorded.

CONDITIONS

Brief Title

Evaluation of the Efficacy of a Probiotic Product as an Adjuvant Treatment for Vulvovaginal Candidiasis

Who Can Participate

FEMALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Women of reproductive age who use effective contraceptive methods during the study
  • Clinical suspicion of vulvovaginal candidiasis based on symptoms or clinical findings
  • Ability to collect a vaginal sample at baseline for microbiological analysis
  • Willingness and ability to comply with study procedures and sign informed consent
Not Eligible

You will not qualify if you...

  • Menstruation at the time of inclusion
  • Pregnancy or breastfeeding
  • Menopause or perimenopause
  • Diabetes mellitus
  • Immunocompromised status or immunosuppressant treatment within 3 months prior
  • Vaginal coinfection besides vulvovaginal candidiasis
  • Severe chronic diseases or active infections interfering with clinical assessment
  • History of intolerance or hypersensitivity to study products
  • Antifungal or probiotic treatment in the month prior to inclusion

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - Up to 2 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person) for screening and enrollment

Treatment

Duration - 4 weeks

Participants receive antifungal treatment with or without a probiotic supplement for vulvovaginal candidiasis.

1 baseline visit and 1 follow-up visit at Week 4

Trial Site Locations

Total: 1 location

1

Hospital Universitario de Torrevieja

Torrevieja, Alicante, Spain, 03186

Actively Recruiting

Loading map...

Research Team

J

Juan Gabriel Agüera Santos

V

Vicente Navarro López

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Open-label Clinical Study of a Vaginal Cooling Device for Tr...

Vulvovaginal Candidiasis (VVC)

Actively Recruiting

10 locations

International Open-label Randomized Study Comparing Clotrima...

Candidal Vulvovaginitis (ICD-10 Code: B37.3)

Actively Recruiting

7 locations

Safety and Efficacy Study to Assess 600 mg Boric Acid Vagina...

Vulvovaginal Candidiases

Actively Recruiting

27 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here